SCHEMBL22614910

SCHEMBL22614910

CS(=O)(=O)N1CCC(Nc2ncc3c(n2)-c2[nH]cnc2CC3)CC1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 20/20 0.65
▸ CCNE1 P24864 17/20 0.65
▸ CCNA2 P20248 4/20 0.55
▸ CCNA1 P78396 4/20 0.55
▸ AURKA O14965 2/20 0.52
▸ CDK1 P06493 7/20 0.50
▸ CCNB1 P14635 7/20 0.50
▸ CDK5 Q00535 4/20 0.50
▸ CDK5R1 Q15078 4/20 0.50
▸ CCNE2 O96020 4/20 0.50
▸ CCNB2 O95067 3/20 0.50
▸ CCNB3 Q8WWL7 3/20 0.50
▸ CDK4 P11802 4/20 0.49
▸ CCND1 P24385 4/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ GSK3B P49841 1/20 0.49
▸ CCND3 P30281 3/20 0.47
▸ CDK6 Q00534 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22612611 0.85 CDK2 (0.74) CDK2CCNE1CCNA2CCNA1AURKA
SCHEMBL22612604 0.79 CDK2 (1.00) CDK2CCNE1CCNA2CCNA1AURKA
SCHEMBL22612650 0.79 CDK2 (0.67) CDK2CCNE1CCNA2CCNA1AURKA
SCHEMBL22612600 0.79 CDK2 (0.64) CDK2CCNE1CCNA2CCNA1AURKA
SCHEMBL24474562 0.78 CDK2 (0.63) CDK2CCNE1CCNA2CCNA1AURKA
SCHEMBL29683327 0.78 CDK2 (0.63) CDK2CCNE1CCNA2CCNA1AURKA
SCHEMBL22612649 0.77 CDK2 (0.63) CDK2CCNE1CCNA2CCNA1AURKA
SCHEMBL22612632 0.77 CDK2 (0.62) CDK2CCNE1CCNA2CCNA1AURKA
SCHEMBL22612641 0.77 CDK2 (0.66) CDK2CCNE1CCNA2CCNA1AURKA
SCHEMBL22612615 0.77 CDK2 (0.64) CDK2CCNE1CCNA2CCNA1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020223469-A1 N-(1-(METHYLSULFONYL)PIPERIDIN-4-YL)-4,5-DI HYDRO-1H-IMIDAZO[4,5-H]QUINAZOLIN-8-AMINE DERIVATIVES AND RELATED COMPOUNDS AS CYCLIN-DEPENDENT KINASE 2 (CDK2) INHIBITORS FOR TREATING CANCER INCYTE CORPORATION (US) 2020-11-05 — — WO disclosed
Send feedback